168 related articles for article (PubMed ID: 18456868)
41. Dopamine agonists and the risk of cardiac-valve regurgitation.
Schade R; Andersohn F; Suissa S; Haverkamp W; Garbe E
N Engl J Med; 2007 Jan; 356(1):29-38. PubMed ID: 17202453
[TBL] [Abstract][Full Text] [Related]
42. Severe mitral valve regurgitation with fatal cardiogenic shock in a patient on long-term cabergoline treatment.
Luedde M; Helmke B; Katus HA; Frey N
Int J Cardiol; 2009 Apr; 133(3):e97-8. PubMed ID: 18191474
[TBL] [Abstract][Full Text] [Related]
43. AACE/ACE Disease State Clinical Review: Dopamine Agonists for Hyperprolactinemia and the Risk of Cardiac Valve Disease.
Samson SL; Ezzat S
Endocr Pract; 2014 Jun; 20(6):608-16. PubMed ID: 24969114
[TBL] [Abstract][Full Text] [Related]
44. Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia.
Valassi E; Klibanski A; Biller BM
J Clin Endocrinol Metab; 2010 Mar; 95(3):1025-33. PubMed ID: 20130078
[TBL] [Abstract][Full Text] [Related]
45. Long-term low-dose cabergoline usage: Another association with cardiac valvulopathy.
Tessier S; Lipton BA; Arastu MI; Curiale AM; Longo S; Nanda S
Echocardiography; 2023 Jan; 40(1):61-64. PubMed ID: 36511080
[TBL] [Abstract][Full Text] [Related]
46. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data.
Caputo C; Prior D; Inder WJ
Lancet Diabetes Endocrinol; 2015 Nov; 3(11):906-13. PubMed ID: 25466526
[TBL] [Abstract][Full Text] [Related]
47. Cabergoline use for pituitary tumors and valvular disorders.
Auriemma RS; Pivonello R; Ferreri L; Priscitelli P; Colao A
Endocrinol Metab Clin North Am; 2015 Mar; 44(1):89-97. PubMed ID: 25732645
[TBL] [Abstract][Full Text] [Related]
48. High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease.
Oeda T; Masaki M; Yamamoto K; Mizuta E; Kitagawa N; Isono T; Taniguchi S; Doi K; Yaku H; Yutani C; Kawamura T; Kuno S; Sawada H
J Neural Transm (Vienna); 2009 Feb; 116(2):171-8. PubMed ID: 19082526
[TBL] [Abstract][Full Text] [Related]
49. Cabergoline and mitral regurgitation.
Delgrange E
N Engl J Med; 2006 Jan; 354(4):420; author reply 420. PubMed ID: 16436779
[No Abstract] [Full Text] [Related]
50. Bromocriptine use and the risk of valvular heart disease.
Tan LC; Ng KK; Au WL; Lee RK; Chan YH; Tan NC
Mov Disord; 2009 Feb; 24(3):344-9. PubMed ID: 18989898
[TBL] [Abstract][Full Text] [Related]
51. Severe tricuspid regurgitation in a patient receiving low-dose cabergoline for the treatment of acromegaly.
Izgi C; Feray H; Cevik C; Saltan Y; Mansuroglu D; Nugent K
J Heart Valve Dis; 2010 Nov; 19(6):797-800. PubMed ID: 21214109
[TBL] [Abstract][Full Text] [Related]
52. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
Kim JY; Chung EJ; Park SW; Lee WY
Mov Disord; 2006 Aug; 21(8):1261-4. PubMed ID: 16685692
[TBL] [Abstract][Full Text] [Related]
53. Mitral heart disease due to cabergoline.
Martin M; Iglesias-Cubero G; Diaz Molina B; Moris De la Tassa C
Int J Cardiol; 2007 Jan; 114(1):e7-8. PubMed ID: 17052783
[TBL] [Abstract][Full Text] [Related]
54. [Aortic insufficiency under weak doses of cabergoline for non-tumoral hyperprolactinemia].
Belleville I; Chague F; Petit JM; Boujon B
Ann Endocrinol (Paris); 2007 Dec; 68(6):464-6. PubMed ID: 17905193
[TBL] [Abstract][Full Text] [Related]
55. Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease.
Nakaoka S; Ishizaki T; Urushihara H; Satoh T; Ikeda S; Morikawa K; Nakayama T
Intern Med; 2011; 50(7):687-94. PubMed ID: 21467699
[TBL] [Abstract][Full Text] [Related]
56. [Two cases of patients with Parkinson's disease developing valvular heart disease while taking cabergoline].
Sato T; Kikuchi A; Onoue N; Hiramoto T; Oumi M; Onodera J
Rinsho Shinkeigaku; 2008 Jul; 48(7):486-91. PubMed ID: 18717182
[TBL] [Abstract][Full Text] [Related]
57. Cardiopulmonary complications of ergot-derivative dopamine agonists.
Rack MJ; Baran AS; Richert AC; Roffwarg HP
J Clin Psychiatry; 2004 Oct; 65(10):1429-30; author reply 1430. PubMed ID: 15491249
[No Abstract] [Full Text] [Related]
58. Valvular heart disease in patients with Parkinson's disease treated with pergolide. Course following treatment modifications.
Dupuy D; Lesbre JP; Gérard P; Andrejak M; Godefroy O
J Neurol; 2008 Jul; 255(7):1045-8. PubMed ID: 18560792
[TBL] [Abstract][Full Text] [Related]
59. [The best of valvular heart disease in 2006].
de Gevigney G;
Arch Mal Coeur Vaiss; 2007 Jan; 100 Spec No 1():19-28. PubMed ID: 17405561
[TBL] [Abstract][Full Text] [Related]
60. Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma.
Khare S; Lila AR; Patil R; Phadke M; Kerkar P; Bandgar T; Shah NS
Indian J Endocrinol Metab; 2017; 21(1):154-159. PubMed ID: 28217516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
